Kaiser Permanente, Johns Hopkins forge partnership

Kaiser Permanente and Johns Hopkins Medicine have announced a strategic partnership to share best practices, advance population health, collaborate on education and research and explore better healthcare models for consumers and communities.

According to a joint announcement, the partners will focus on:

  • Sharing best practices and leveraging EMRs to accommodate the growing need among providers and patients to access clinical information quickly and efficiently.
  • Strengthening the relationship between Kaiser Permanente and Suburban Hospital, a member of Johns Hopkins Medicine, by combining their collective expertise to create an advanced model of care.
  • Exploring home care and leveraging technology to deliver personalized medicine.
  • Building on the existing collaboration between Kaiser Permanente and Johns Hopkins’ Armstrong Institute for Patient Safety and Quality to advance the patient experience and improve treatment outcomes while reducing costs.
  • Pursuing opportunities to develop educational programs and research-based best practices that benefit the overall health of the people in the communities we serve.

“Healthcare today requires partnership among forward-thinking healthcare organizations,” said Paul B. Rothman, MD, dean of the medical faculty and CEO of Johns Hopkins Medicine, in a statement. “Through a strategic collaboration with Kaiser Permanente, we will be able to cultivate the human and intellectual capital found in both organizations to significantly improve the safety and quality of care while enhancing the patient experience.”

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.